Background Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal
junction adenocarcinoma. This study reports on the safety and efficacy of the …

Background Cetuximab and bevacizumab have both been shown to improve outcomes in
patients with metastatic colorectal cancer when added to chemotherapy regimens; however, …

Purpose The phase III CRYSTAL study demonstrated that addition of cetuximab to fluorouracil,
leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival, progression-…

Purpose To compare the effectiveness and tolerability of gemcitabine plus cisplatin with
single-agent gemcitabine as first-line chemotherapy for locally advanced or metastatic …

Background Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts
and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. …

In this work, we report the set-up and results of the Liver Tumor Segmentation Benchmark (LiTS),
which was organized in conjunction with the IEEE International Symposium on …

Gemcitabine (dFdC) is a new anticancer nucleoside that is an analog of deoxycytidine. It is
a pro-drug and, once transported into the cell, must be phosphorylated by deoxycytidine …

Background: Positive findings from the phase III MPACT trial led to the regulatory approval
of nab-paclitaxel plus gemcitabine as a treatment option for patients with metastatic …

Importance Metastatic colorectal cancer (mCRC) is heterogeneous, and primary tumors
arising from different regions of the colon are clinically and molecularly distinct. Objective To …

2′,2′-Difluorodeoxycytidine (dFdC) is a new deoxycytidine analogue with good activity
against human leukemic cell lines and murine solid tumors, while the activity of 1-β-d -…